Praxis Precision Medicines Shares Rise on Positive Preliminary Meeting with FDA for Essential Tremor Treatment

Dow Jones12-05

By Adriano Marchese

Shares is Praxis Precision Medicines rose in premarket trading Friday after it said it expects to submit to U.S. regulators a new drug application next year for its investigational drug to treat essential tremors.

Shares traded 25% higher ahead of the morning bell at $237.10.

The clinical-stage biopharmaceutical company said Thursday that it expects to submit its NDA early in 2026 after a preliminary meeting with the Food and Drug Administration regarding its drug ulixacaltamide.

Ulixacaltamide is Praxis' investigational drug aimed at treating essential tremors, a neurological movement disorder that causes involuntary shaking, most often in the hands, but it also can affect other body parts such as the head or the voice. It is the most common type of tremor and is distinct from Parkinson's disease.

From its meeting with the FDA, Praxis said it has reached an understanding with regulators on the required content of the application and anticipates completing the submission early next year.

Write to Adriano Marchese at adriano.marchese@wsj.com

(END) Dow Jones Newswires

December 05, 2025 06:33 ET (11:33 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589578891?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-05 19:33","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589578891","market":"sh","top_or_hot":-1,"title":"Praxis Precision Medicines Shares Rise on Positive Preliminary Meeting with FDA for Essential Tremor Treatment","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares is <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> rose in premarket trading Friday after it said it expects to submit to U.S. regulators a new drug application next year for its investigational drug to treat essential tremors. \n</p>\n<p>\n  Shares traded 25% higher ahead of the morning bell at $237.10. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Thursday that it expects to submit its NDA early in 2026 after a preliminary meeting with the Food and Drug Administration regarding its drug ulixacaltamide. \n</p>\n<p>\n  Ulixacaltamide is Praxis' investigational drug aimed at treating essential tremors, a neurological movement disorder that causes involuntary shaking, most often in the hands, but it also can affect other body parts such as the head or the voice. It is the most common type of tremor and is distinct from Parkinson's disease. \n</p>\n<p>\n  From its meeting with the FDA, Praxis said it has reached an understanding with regulators on the required content of the application and anticipates completing the submission early next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 05, 2025 06:33 ET (11:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Praxis Precision Medicines Shares Rise on Positive Preliminary Meeting with FDA for Essential Tremor Treatment</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nPraxis Precision Medicines Shares Rise on Positive Preliminary Meeting with FDA for Essential Tremor Treatment\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-12-05 19:33</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Adriano Marchese \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Shares is <a href=\"https://laohu8.com/S/PRAX\">Praxis Precision Medicines</a> rose in premarket trading Friday after it said it expects to submit to U.S. regulators a new drug application next year for its investigational drug to treat essential tremors. \n</p>\n<p>\n  Shares traded 25% higher ahead of the morning bell at $237.10. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said Thursday that it expects to submit its NDA early in 2026 after a preliminary meeting with the Food and Drug Administration regarding its drug ulixacaltamide. \n</p>\n<p>\n  Ulixacaltamide is Praxis' investigational drug aimed at treating essential tremors, a neurological movement disorder that causes involuntary shaking, most often in the hands, but it also can affect other body parts such as the head or the voice. It is the most common type of tremor and is distinct from Parkinson's disease. \n</p>\n<p>\n  From its meeting with the FDA, Praxis said it has reached an understanding with regulators on the required content of the application and anticipates completing the submission early next year. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  December 05, 2025 06:33 ET (11:33 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2589578891","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589578891","pubTimestamp":1764934380,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"Shares is Praxis Precision Medicines rose in premarket trading Friday after it said it expects to submit to U.S. regulators a new drug application next year for its investigational drug to treat essential tremors.Shares traded 25% higher ahead of the morning bell at $237.10.The clinical-stage biopharmaceutical company said Thursday that it expects to submit its NDA early in 2026 after a preliminary meeting with the Food and Drug Administration regarding its drug ulixacaltamide.Ulixacaltamide is Praxis' investigational drug aimed at treating essential tremors, a neurological movement disorder that causes involuntary shaking, most often in the hands, but it also can affect other body parts such as the head or the voice. It is the most common type of tremor and is distinct from Parkinson's disease.From its meeting with the FDA, Praxis said it has reached an understanding with regulators on the required content of the application and anticipates completing the submission early next year.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","PRAX":"Praxis Precision Medicines, Inc.","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC"},"translate_title":"Praxis Precision Medicines股价因与FDA就特发性震颤治疗举行积极初步会议而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1.5},"content_text":"By Adriano Marchese \n\n\n \n\n\n  Shares is Praxis Precision Medicines rose in premarket trading Friday after it said it expects to submit to U.S. regulators a new drug application next year for its investigational drug to treat essential tremors. \n\n\n  Shares traded 25% higher ahead of the morning bell at $237.10. \n\n\n  The clinical-stage biopharmaceutical company said Thursday that it expects to submit its NDA early in 2026 after a preliminary meeting with the Food and Drug Administration regarding its drug ulixacaltamide. \n\n\n  Ulixacaltamide is Praxis' investigational drug aimed at treating essential tremors, a neurological movement disorder that causes involuntary shaking, most often in the hands, but it also can affect other body parts such as the head or the voice. It is the most common type of tremor and is distinct from Parkinson's disease. \n\n\n  From its meeting with the FDA, Praxis said it has reached an understanding with regulators on the required content of the application and anticipates completing the submission early next year. \n\n\n \n\n\n  Write to Adriano Marchese at adriano.marchese@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  December 05, 2025 06:33 ET (11:33 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"policyRegulatory","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.10","shortVersion":"4.35.10","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589578891","isCrawlerRequest":true}